Navigation Links
Luminex Corporation Fourth Quarter and Full Year 2010 Earnings Release Scheduled for February 7, 2011
Date:1/18/2011

AUSTIN, Texas, Jan. 18, 2011 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter and full year 2010 on Monday, February 7, 2011. A press release announcing the results is scheduled for release after the close of trading.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and full year ended December 31, 2010, on February 7, 2011, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an openarchitecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.Luminex Corporate Contact:Harriss T. CurrieVice President, Finance and Chief Financial Officer512-219-8020Luminex Investor Relations Contact:Matthew D. ScaloSr. Director of Investor Relations512-219-8020mscalo@luminexcorp.com
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
3. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
4. Luminex Corporation to Present at UBS Global Life Sciences Conference
5. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
6. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
7. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
8. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
9. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
10. Luminex Corporation Reports Third Quarter 2010 Results
11. Luminex Corporation to Present at Stephens Fall Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... MIAMI , February 23, 2017 ML ... stake in Colorado Highlife Tours , a ... strategic plan in partnership with Puration, Inc. (USOTC: PURA) to enter ... luxury cannabis tours product. The Colorado Highlife Tours acquisition announced today ... cannabis tourism strategy. ...
(Date:2/23/2017)... , Feb. 23, 2017 Provectus Biopharmaceuticals, Inc. ... a clinical-stage oncology and dermatology biopharmaceutical company, today announced ... Dominic Rodrigues as special advisers to the ... will advise the board on financial and corporate strategy. ... an investment commitment of up to $2.5 million from ...
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 /PRNewswire/ ... to the non-hodgkin lymphoma partnering deals and agreements ... Read the full report: http://www.reportlinker.com/p03605669-summary/view-report.html ... and Agreements since 2010 report provides understanding and ... by the world,s leading healthcare companies. ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® ... the fight against cancer, has produced a seminal study that asked cancer survivors ... top-line findings in a webinar, Defining Compassionate Care Through the Voices of Patients ...
(Date:2/23/2017)... ... (PRWEB) February ... for the nation to come together to combine its favorite ... with its favorite fruit – apples! To celebrate National Nutrition ... join the “Apple Madness” bracket tournament – a five-week, five-round ...
(Date:2/23/2017)... ... 23, 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti ... new Indiegogo campaign . Individuals are now able to contribute to the local ... either as a participating patient or through an Indiegogo donation. The entirety of proceeds ...
(Date:2/23/2017)... ... 23, 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior ... to the Minneapolis Home and Garden Show which is being held February 24 through ... attention is the Minneapolis Convention Center. , From its broad line of sit ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez has ... also continued to spiritually evolve, which is the purpose of everyone in this universe. ... Truths ” (published by Balboa Press) attempts to guide readers to expand one’s spiritual ...
Breaking Medicine News(10 mins):